Advertisement


Laura C. Michaelis, MD: In My Experience Question 1

COVID-19 and Cancer Care

Advertisement

How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?

Recorded April 24, 2020.



Related Videos

COVID-19

Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations

Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.

COVID-19

Nancy E. Davidson, MD, on COVID-19 and Cancer Care: Thoughts From the Seattle Epicenter

Nancy E. Davidson, MD, of the Seattle Cancer Care Alliance, and a member of The ASCO Post Editorial Board, talks about her experiences in one of the communities hardest hit by coronavirus and offers some practical advice on making changes in treatment and research. Recorded April 7, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 2

During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission?

Recorded April 21, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 1

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 6

Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic?

Recorded April 21, 2020.

Advertisement

Advertisement



Advertisement